Drugs / GV101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05068947 | Sep → Oct 2021 | — | Graviton Bioscience Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06979505 | Jun 2025 → Jan 2026 | — | Graviton Bioscience Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GV101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06979505 ↗ |
| Route | Oral | “GV101 administered once orally.” NCT05068947 ↗ |